JP7496686B2 - 骨髄増殖性腫瘍関連骨髄線維症及び貧血を治療するための方法 - Google Patents

骨髄増殖性腫瘍関連骨髄線維症及び貧血を治療するための方法 Download PDF

Info

Publication number
JP7496686B2
JP7496686B2 JP2019569312A JP2019569312A JP7496686B2 JP 7496686 B2 JP7496686 B2 JP 7496686B2 JP 2019569312 A JP2019569312 A JP 2019569312A JP 2019569312 A JP2019569312 A JP 2019569312A JP 7496686 B2 JP7496686 B2 JP 7496686B2
Authority
JP
Japan
Prior art keywords
subject
actriib
seq
signaling inhibitor
specific embodiment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019569312A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020524139A (ja
JP2020524139A5 (https=
Inventor
ラアデム アブデラフマネ
ガレ ロバート
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64660712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7496686(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of JP2020524139A publication Critical patent/JP2020524139A/ja
Publication of JP2020524139A5 publication Critical patent/JP2020524139A5/ja
Priority to JP2024027645A priority Critical patent/JP2024075579A/ja
Application granted granted Critical
Publication of JP7496686B2 publication Critical patent/JP7496686B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/1103—Receptor protein serine/threonine kinase (2.7.11.30)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2019569312A 2017-06-14 2018-06-13 骨髄増殖性腫瘍関連骨髄線維症及び貧血を治療するための方法 Active JP7496686B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024027645A JP2024075579A (ja) 2017-06-14 2024-02-27 骨髄増殖性腫瘍関連骨髄線維症及び貧血を治療するための方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762519725P 2017-06-14 2017-06-14
US62/519,725 2017-06-14
US201862679210P 2018-06-01 2018-06-01
US62/679,210 2018-06-01
PCT/US2018/037213 WO2018231905A1 (en) 2017-06-14 2018-06-13 Methods for treating myeloproliferative neoplasm-associated myelofibrosis and anemia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024027645A Division JP2024075579A (ja) 2017-06-14 2024-02-27 骨髄増殖性腫瘍関連骨髄線維症及び貧血を治療するための方法

Publications (3)

Publication Number Publication Date
JP2020524139A JP2020524139A (ja) 2020-08-13
JP2020524139A5 JP2020524139A5 (https=) 2021-07-29
JP7496686B2 true JP7496686B2 (ja) 2024-06-07

Family

ID=64660712

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019569312A Active JP7496686B2 (ja) 2017-06-14 2018-06-13 骨髄増殖性腫瘍関連骨髄線維症及び貧血を治療するための方法
JP2024027645A Pending JP2024075579A (ja) 2017-06-14 2024-02-27 骨髄増殖性腫瘍関連骨髄線維症及び貧血を治療するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024027645A Pending JP2024075579A (ja) 2017-06-14 2024-02-27 骨髄増殖性腫瘍関連骨髄線維症及び貧血を治療するための方法

Country Status (16)

Country Link
US (1) US20200101134A1 (https=)
EP (2) EP4454707A3 (https=)
JP (2) JP7496686B2 (https=)
CN (1) CN111050770A (https=)
DK (1) DK3638243T3 (https=)
ES (1) ES2991738T3 (https=)
FI (1) FI3638243T3 (https=)
HR (1) HRP20241477T1 (https=)
HU (1) HUE068733T2 (https=)
LT (1) LT3638243T (https=)
PL (1) PL3638243T3 (https=)
PT (1) PT3638243T (https=)
RS (1) RS66093B1 (https=)
SI (1) SI3638243T1 (https=)
SM (1) SMT202400437T1 (https=)
WO (1) WO2018231905A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
JP2018501307A (ja) 2014-12-03 2018-01-18 セルジーン コーポレイション アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用
CN108350057A (zh) 2015-05-20 2018-07-31 细胞基因公司 使用II型活化素受体配体阱的用于β-地中海贫血的体外细胞培养方法
MA45811A (fr) 2016-07-27 2019-06-05 Acceleron Pharma Inc Méthodes et compositions de traitement de maladie.
NZ754161A (en) 2016-11-10 2025-11-28 Keros Therapeutics Inc Activin receptor type iia variants and methods of use thereof
IL320014A (en) 2018-01-12 2025-06-01 Keros Therapeutics Inc Activin receptor type iib variants and methods of use thereof
KR20250133994A (ko) 2018-05-09 2025-09-09 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법
JP7663502B2 (ja) * 2018-10-31 2025-04-16 セルジーン コーポレイション 環状鉄芽球が見られる対象における非常に低リスク、低リスクまたは中程度のリスクの骨髄異形成症候群による貧血の、アクチビン－ａｃｔｒｉｉリガンドトラップを用いた治療
US20220372135A1 (en) 2019-09-27 2022-11-24 Disc Medicine, Inc. Methods for treating myelofibrosis and related conditions
WO2021189010A1 (en) 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
WO2021189019A1 (en) 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Activin receptor type ii chimeras and methods of use thereof
US20230181690A1 (en) * 2020-04-13 2023-06-15 Celgene Corporation Methods for treating anemia using an actriib ligand trap and fedratinib
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
CA3177632A1 (en) * 2020-05-15 2021-11-18 Melih ACAR Methods and compositions for treating anemia using actriib ligand traps and mtor inhibitors
US12186370B1 (en) 2020-11-05 2025-01-07 Celgene Corporation ACTRIIB ligand trap compositions and uses thereof
WO2022271716A2 (en) * 2021-06-21 2022-12-29 Keros Therapeutics, Inc. Methods of using activin receptor type ii signaling inhibitors
KR20240051971A (ko) * 2021-08-19 2024-04-22 케로스 테라퓨틱스, 인크. 액티빈 수용체 ii형 신호전달 억제제를 이용한 방법
WO2025137373A1 (en) * 2023-12-19 2025-06-26 Cellarity, Inc. Disease detection systems and methods

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130243743A1 (en) 2011-10-17 2013-09-19 Acceleron Pharma, Inc. Methods and compositions for treating ineffective erythropoiesis
WO2015192111A1 (en) 2014-06-13 2015-12-17 Acceleron Pharma, Inc. Methods and compositions for treating ulcers
US20170037100A1 (en) 2015-08-04 2017-02-09 Acceleron Pharma Inc. Methods for treating myeloproliferative disorders
WO2017091706A1 (en) 2015-11-23 2017-06-01 Acceleron Pharma Inc. Methods for treating eye disorders

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
NZ306767A (en) 1995-04-11 2000-03-27 Univ Johns Hopkins Method of identifying molecular interactions employing counterselection and at least two hybrid molecules or two hybrid systems
JP2008507288A (ja) 2004-07-23 2008-03-13 アクセルロン ファーマ インコーポレーテッド ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物
US20100028332A1 (en) 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
TW201803890A (zh) 2007-02-02 2018-02-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
TW201803586A (zh) 2008-08-14 2018-02-01 艾瑟勒朗法瑪公司 使用ｇｄｆ阱以增加紅血球水平
AU2010282361B2 (en) 2009-08-13 2015-03-19 Acceleron Pharma Inc. Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels
JP2017509647A (ja) 2014-03-21 2017-04-06 アクセルロン ファーマ， インコーポレイテッド アクチビンｂおよび／またはｇｄｆ１１の阻害によって赤血球レベルを増大させ、無効赤血球生成を処置する方法
JP2018501307A (ja) 2014-12-03 2018-01-18 セルジーン コーポレイション アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用
US20180125928A1 (en) * 2015-05-13 2018-05-10 Celgene Corporation Treatment of beta-thalassemia using actrii ligand traps
MA45811A (fr) 2016-07-27 2019-06-05 Acceleron Pharma Inc Méthodes et compositions de traitement de maladie.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130243743A1 (en) 2011-10-17 2013-09-19 Acceleron Pharma, Inc. Methods and compositions for treating ineffective erythropoiesis
WO2015192111A1 (en) 2014-06-13 2015-12-17 Acceleron Pharma, Inc. Methods and compositions for treating ulcers
US20170037100A1 (en) 2015-08-04 2017-02-09 Acceleron Pharma Inc. Methods for treating myeloproliferative disorders
WO2017091706A1 (en) 2015-11-23 2017-06-01 Acceleron Pharma Inc. Methods for treating eye disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Blood, 2016.12.02, Vol.128, No.22, pp.478，https://ashpublications.org/blood/article/128/22/478/99423/Phase-2-Study-of-Sotatercept-ACE-011-in

Also Published As

Publication number Publication date
JP2020524139A (ja) 2020-08-13
JP2024075579A (ja) 2024-06-04
RS66093B1 (sr) 2024-11-29
EP3638243B1 (en) 2024-08-07
WO2018231905A1 (en) 2018-12-20
EP3638243A1 (en) 2020-04-22
ES2991738T3 (es) 2024-12-04
EP4454707A3 (en) 2024-12-25
US20200101134A1 (en) 2020-04-02
SMT202400437T1 (it) 2024-11-15
PT3638243T (pt) 2024-10-31
HUE068733T2 (hu) 2025-01-28
EP4454707A2 (en) 2024-10-30
LT3638243T (lt) 2024-11-11
HRP20241477T1 (hr) 2025-01-03
SI3638243T1 (sl) 2025-03-31
PL3638243T3 (pl) 2025-02-10
DK3638243T3 (da) 2024-10-28
WO2018231905A8 (en) 2020-01-30
CN111050770A (zh) 2020-04-21
EP3638243A4 (en) 2021-03-17
FI3638243T3 (fi) 2024-10-29

Similar Documents

Publication Publication Date Title
JP7496686B2 (ja) 骨髄増殖性腫瘍関連骨髄線維症及び貧血を治療するための方法
JP6976859B2 (ja) ＡｃｔＲＩＩリガンドトラップを用いたβ−サラセミアの治療
AU2015358469B2 (en) Activin-ActRII antagonists and uses for treating anemia
CN101687015B (zh) 活化素-actrii拮抗剂及在提高红细胞水平中的用途
US20230142386A1 (en) Activin-actrii antagonists and uses for treating anemia
HK1245397B (en) Activin-actrii antagonists and uses for treating myelodysplastic syndrome
HK1226958A1 (en) Activin-actrii antagonists and uses for increasing red blood cell levels

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210611

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210611

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220705

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230104

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230322

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230801

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231031

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240227

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240307

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240514

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240528

R150 Certificate of patent or registration of utility model

Ref document number: 7496686

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150